#### NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# **NICE** guidelines

### Equality impact assessment

# **Diverticular disease**

The impact on equality has been assessed during guidance development according to the principles of the NICE equality policy.

# 4.0 Final guideline (to be completed by the Developer before GE consideration of final guideline)

4.1 Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed them?

No further issues identified

4.2 If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access services compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No changes made that would make it more difficult in practice for a specific group to access services compared with other groups

4.3 If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

#### **1.0.7 DOC EIA**

4.3 If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

4.4 If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access to services identified in questions 4.1, 4.2 and 4.3, or otherwise fulfil NICE's obligations to advance equality?

No

4.5 Have the Committee's considerations of equality issues been described in the final guideline, and, if so, where?

These have been referred to in the committee's discussion of the evidence (reports signs and symptoms of diverticular disease, referral criteria for acute diverticulitis and management of diverticular disease)

Updated by Developer: Sharon Swain

Date: 16 September 2019

Approved by NICE quality assurance lead: Chris Carson

Date: 22 November 2019